Patents by Inventor Marcus Branschaedel

Marcus Branschaedel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10519217
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 31, 2019
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel
  • Publication number: 20190016780
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: June 15, 2018
    Publication date: January 17, 2019
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel
  • Patent number: 10000550
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: June 19, 2018
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Publication number: 20170081386
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Marcus BRANSCHÄDEL
  • Patent number: 9527897
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: December 27, 2016
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Patent number: 9469681
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 18, 2016
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Publication number: 20160176941
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN, Marcus BRANSCHÄDEL
  • Patent number: 9212211
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 15, 2015
    Assignee: APOGENIX GMBH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Publication number: 20150126710
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 7, 2015
    Inventors: Oliver HILL, Marcus Branschädel, Christian Gieffers, Meinolf Thiemann
  • Publication number: 20150126709
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: July 2, 2014
    Publication date: May 7, 2015
    Inventors: Oliver HILL, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Patent number: 8907063
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: December 9, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Publication number: 20140171622
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Application
    Filed: January 21, 2014
    Publication date: June 19, 2014
    Applicant: APOGENIX GMBH
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Patent number: 8664366
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 4, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Patent number: 8383774
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: February 26, 2013
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Publication number: 20120041181
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Application
    Filed: January 9, 2009
    Publication date: February 16, 2012
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Publication number: 20110008326
    Abstract: The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders. Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods for treatment and/or prevention of tumors, inflammatory and immunological disorders, the methods comprising administering to an individual in need thereof an antigen-binding agent with binding affinity for IL-4R.
    Type: Application
    Filed: March 30, 2009
    Publication date: January 13, 2011
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann, Christian Merz
  • Publication number: 20100199364
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: July 10, 2008
    Publication date: August 5, 2010
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel